Stefan Nierkens
Overview
Explore the profile of Stefan Nierkens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
3288
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Mazur N, Lowensteyn Y, Terstappen J, Leusen J, Schobben F, Cianci D, et al.
EClinicalMedicine
. 2024 Jan;
66:102324.
PMID: 38192587
Background: Mucosal administration of monoclonal antibodies (mAbs) against respiratory pathogens is a promising alternative for systemic administration because lower doses are required for protection. Clinical development of mucosal mAbs is...
22.
Wienke J, Visser L, Kholosy W, Keller K, Barisa M, Poon E, et al.
Cancer Cell
. 2024 Jan;
42(2):283-300.e8.
PMID: 38181797
Pediatric patients with high-risk neuroblastoma have poor survival rates and urgently need more effective treatment options with less side effects. Since novel and improved immunotherapies may fill this need, we...
23.
Koedijk J, van der Werf I, Penter L, Vermeulen M, Barneh F, Perzolli A, et al.
medRxiv
. 2023 Nov;
PMID: 37961528
Because of the low mutational burden and consequently, fewer potential neoantigens, children with acute myeloid leukemia (AML) are thought to have a T cell-depleted or 'cold' tumor microenvironment and may...
24.
Koedijk J, van Beek T, Vermeulen M, Kester L, Schweighart E, Nierkens S, et al.
Front Immunol
. 2023 Nov;
14:1280885.
PMID: 37908360
Regression of leukemia in the absence of disease-modifying therapy remains poorly understood, although immunological mechanisms are thought to play a role. Here, we present a unique case of a 17-year-old...
25.
van Eijs M, Verheijden R, van der Wees S, Nierkens S, van Lindert A, Suijkerbuijk K, et al.
Cancer Immunol Immunother
. 2023 Oct;
72(12):4049-4064.
PMID: 37794264
Immune checkpoint inhibitors (ICI) have revolutionized the treatment landscape of advanced malignancies, but come with a diverse spectrum of immune-related adverse events (irAEs). Mechanistic studies can aid the transition from...
26.
van Eijs M, Ter Linde J, Baars M, Amini M, Lacle M, Brand E, et al.
iScience
. 2023 Sep;
26(10):107891.
PMID: 37766980
Colitis is a prevalent adverse event associated with immune checkpoint inhibitor (ICI) therapy with similarities to inflammatory bowel disease. Incomplete mechanistic understanding of ICI colitis curtails evidence-based treatment. Given the...
27.
Chiu Y, Drijver A, Admiraal R, van Rhenen A, Nierkens S, van Laar J, et al.
J Scleroderma Relat Disord
. 2023 Sep;
8(3):241-246.
PMID: 37744043
Introduction: Autologous haematopoietic stem cell transplantation improves event-free survival and lung function and reduces skin thickening in patients with progressive diffuse cutaneous systemic sclerosis. Anti-thymocyte globulin is a key lymphoablative...
28.
Verbeek M, Rodriguez B, Sedek L, Laqua A, Buracchi C, Buysse M, et al.
Cytometry B Clin Cytom
. 2023 Sep;
106(4):252-263.
PMID: 37740440
Presence of minimal residual disease (MRD), detected by flow cytometry, is an important prognostic biomarker in the management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, data-analysis remains mainly expert-dependent....
29.
Schneider P, Crump N, Arentsen-Peters S, Smith A, Hagelaar R, Adriaanse F, et al.
Exp Hematol Oncol
. 2023 Sep;
12(1):81.
PMID: 37740239
In KMT2A-rearranged acute lymphoblastic leukemia (ALL), an aggressive malignancy, oncogenic KMT2A-fusion proteins inappropriately recruit DOT1L to promote leukemogenesis, highlighting DOT1L as an attractive therapeutic target. Unfortunately, treatment with the first-in-class...
30.
Bugarin C, Antolini L, Buracchi C, Matarraz S, Coliva T, Van der Velden V, et al.
Haematologica
. 2023 Aug;
109(2):521-532.
PMID: 37534527
Diagnostic criteria for juvenile myelomonocytic leukemia (JMML) are currently well defined, however in some patients diagnosis still remains a challenge. Flow cytometry is a well established tool for diagnosis and...